Clinical trials: Arterial Insufficiency
Atherosclerosis
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
In accordance with the recently revised FDA draft renal impairment guidance (March 2010) which advises the conduct of renal impairment study in drugs that are not predominately eliminated through the renal route, the proposed…
- Trial name
- NCT01711723
- Testing
- Darapladib 160 mg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Hemodialysis
Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)
The most common co-morbidity accompanying Chronic Kidney Disease (CKD) is hypertension, which appears in approximately 80% of all patients with renal dysfunction, whereas its prevalence in general population is remarkably lower…
- Conditions
- Chronic Kidney Disease, Hemodialysis, Hypertension
- Trial name
- LUST ABPM (NCT03058874)
- Testing
- Extra-vascular lung water measurements by ultrasound, Standard protocol of fluid management in hemodialysis
- Where
- 2 sites in Greece, Slovenia
- Volunteers
- 71 people
- Sponsor
- Carmine Zoccali
Oxidative Stress, Inflammation
CoQ10 Biomarker Trial
The investigators believe that relieving the oxidative stress experienced by hemodialysis patients may help improve cardiovascular health.
- Conditions
- Oxidative Stress, Inflammation, Endothelial Dysfunction
- Trial name
- NCT01408680
- Testing
- Coenzyme Q10
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
Coronary Artery Disease, Aortic Valve Disorder
Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards PERIMOUNT Magna Ease Valves in patients undergoing aortic valve replacement with or without concomitant procedures…
- Conditions
- Coronary Artery Disease, Aortic Valve Disorder, Heart Failure, Aortic Valve Stenosis
- Trial name
- NCT01171625
- Testing
- Implantation of CEP Magna Ease Model 3300TFX
- Where
- 13 sites in United States, Austria and 4 more
- Volunteers
- 283 people
- Sponsor
- Edwards Lifesciences
Mitral Insufficiency, Pulmonary Arterial Hypertension
Surgical Valvuloplasty for Congenital Mitral Insufficiency
Congenital mitral insufficiency is one of the most common valvular diseases in the pediatric population worldwide, carrying a high morbidity and mortality risk if not treated immediately and properly.
- Trial name
- NCT03567668
- Testing
- mitral valvuloplasty
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hong Liu
Hypertension
A Trial of Telmisartan Prevention of Cardiovascular Disease
The present research is conducted as a randomized, parallel-group, controlled, open study (using the PROBE method) to primarily verify the effects on various biomarkers in high-risk hypertensive patients treated with ARB…
- Trial name
- ATTEMPT-CVD (NCT01075698)
- Testing
- Non-ARB (standard therapy), ARB (Telmisartan)
- Where
- Japan
- Volunteers
- 1,228 people
- Sponsor
- Kumamoto University
Arterial Stiffness, CHRONIC RENAL FAILURE
Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.
The aims of the presented study are as follows: 1. To evaluate the endothelial function and arterial stiffness in a large cohort of prevalent CKD patients by means of non-invasive applantion tonometry. 2.
- Conditions
- Arterial Stiffness, CHRONIC RENAL FAILURE, Left Ventricular Hypertrophy
- Trial name
- NCT01579032
- Where
- 2 sites in Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
End-stage Kidney Disease
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
The purpose of this study is to see if vitamin K supplementation three times per week reduces the progression of coronary artery calcification over 12 months in dialysis patients compared to placebo.
- Trial name
- iPACK-HD (NCT01528800)
- Testing
- Vitamin K1, Microcrystalline Methylcellulose
- Where
- 3 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Dr. Rachel Holden
Valvular Disease, Valvular Heart Disease
Epidemiology and Long-term Outcome of Patients With VHD
Valvular heart diseases are significant problem in Polish population. Coexistence of coronary artery disease in patients with VHD increases the risk of death and affects further therapeutic strategy.
- Conditions
- Valvular Disease, Valvular Heart Disease, Aortic Valve Stenosis, Mitral Insufficiency and Aortic Stenosis
- Trial name
- BIA-WAD (NCT04527367)
- Testing
- Innovative medical technologies in invasive cardiology and cardiac surgery
- Where
- Poland
- Volunteers
- 2,500 people
- Sponsor
- Medical University of Bialystok
Coronary Artery Disease, End Stage Renal Disease
Coronary Revascularization in Patients On Dialysis in China-Retrospective Registry
Coronary artery disease (CAD) is the leading cause of death in end-stage renal disease (ESRD) patients requiring dialysis. There are limited data on clinical characteristics, treatment strategies and outcomes in this special…
- Conditions
- Coronary Artery Disease, End Stage Renal Disease, Dialysis
- Trial name
- CRUISE-R (NCT05841082)
- Where
- China
- Volunteers
- 1,249 people
- Sponsor
- China-Japan Friendship Hospital
Chronic Kidney Disease
Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects
This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.
- Trial name
- FCRD01 (NCT00810732)
- Testing
- Open, Nifedipine
- Where
- 2 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Pfizer
Low Tidal Volume Ventilation, Acute Respiratory Distress Syndrome
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
The purpose of this protocol is to perform serial physiological measurements and blood testing on mechanically ventilated patients comparing conditions of eucapnia and hypercapnia in the same patient.
- Trial name
- NCT01927237
- Testing
- HLR, EHR
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Coronary Disease, Myocardial Infarction
Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study
The CLIMATE Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific efforts, somatosensory amplification, self-efficacy, health…
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Failure, Arrhythmias, Cardiac
- Trial name
- CLIMATE (NCT05961163)
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Kidney Disease
Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
Patients with Chronic Kidney Disease (CKD) have a poor prognosis primarily due to cardiovascular disease. The cardiovascular risk can be assessed by measurements of arterial stiffness.
- Trial name
- ALBLOCK-2 (NCT01100203)
- Testing
- Eplerenone
- Where
- 2 sites in Denmark
- Volunteers
- 54 people
- Sponsor
- Lene Boesby
End Stage Renal Disease on Dialysis
pH, Hypoxia and Haemodialysis
End-stage renal disease typically requires haemodialysis to help replace kidney function. However, changes in oxygen uptake during haemodialysis have been linked to increased all-cause mortality.
- Trial name
- pHHd (NCT04501159)
- Testing
- blood sample pre, during and post HD, Non invasive cardiac output assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Coventry University
Healthy Participants
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
- Trial name
- NCT06942923
- Testing
- AZD4144
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Failure, Hemodynamics
Hemodynamic Assessment APCO Monitor vs Crit Line for Renal Replacement Rx
Fluid and volume management are a challenging part of critical care and the difficulties increase in the face of renal failure. Utilizing the Crit-Line to monitor blood volume changes in conjunction with arterial pressure cardiac…
- Trial name
- APCOvC-Line (NCT00666003)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Baystate Medical Center
Renal Artery Stenosis, Ischemic Nephropathy
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at recovering kidney function. For this reason we are studying a stem cell product called "mesenchymal stem cells" or MSC.
- Conditions
- Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
- Trial name
- NCT02266394
- Testing
- Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease, Acute Liver Failure
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct
Coronary Artery Disease (CAD) is the narrowing or blockage of the artery of the heart and is prevalent in end-stage liver disease.
- Conditions
- Coronary Artery Disease, Acute Liver Failure, Liver Transplant
- Trial name
- CRASCH-Liver (NCT04089969)
- Testing
- CTA/FFRct, SOC cardiovascular evaluation
- Sponsor
- Corewell Health East